Achieving flexibility & scalability in cell therapy manufacturing through optimized cell isolation & activation

Manufacturing challenges within the cell therapy field continuously center around patient safety, cost reduction, process scalability, and establishing workflows that are both closed and automated. Many cell therapy manufacturers are currently concentrating on autologous CAR-T cell processes. However, as the space becomes more mature, cell therapy will shift its focus to allogeneic off-the-shelf therapies whilst simultaneously continuing to optimize autologous drug efficacy and cost. This will amplify the need for flexible solutions that can support both autologous and allogeneic processes for cell therapy companies everywhere. This article explores one such solution–the Gibco™ CTS™ Detachable Dynabeads™ platform.

Please enter your email to access content Read now